28 research outputs found
Measuring the Invisible Higgs Width at the 7 and 8 TeV LHC
The LHC is well on track toward the discovery or exclusion of a light
Standard Model (SM)-like Higgs boson. Such a Higgs has a very small SM width
and can easily have large branching fractions to physics beyond the SM, making
Higgs decays an excellent opportunity to observe new physics. Decays into
collider-invisible particles are particularly interesting as they are
theoretically well motivated and relatively clean experimentally. In this work
we estimate the potential of the 7 and 8 TeV LHC to observe an invisible Higgs
branching fraction. We analyze three channels that can be used to directly
study the invisible Higgs branching ratio at the 7 TeV LHC: an invisible Higgs
produced in association with (i) a hard jet; (ii) a leptonic Z; and (iii)
forward tagging jets. We find that the last channel, where the Higgs is
produced via weak boson fusion, is the most sensitive, allowing branching
fractions as small as 40% to be probed at 20 inverse fb for masses in the range
between 120 and 170 GeV, including in particular the interesting region around
125 GeV. We provide an estimate of the 8 TeV LHC sensitivity to an
invisibly-decaying Higgs produced via weak boson fusion and find that the reach
is comparable to but not better than the reach at the 7 TeV LHC. We further
estimate the discovery potential at the 8 TeV LHC for cases where the Higgs has
substantial branching fractions to both visible and invisible final states.Comment: 23 pages, 7 figures. v2: version published in JHEP. 8 TeV analysis
adde
Neutrino Mass and from a Mini-Seesaw
The recently proposed "mini-seesaw mechanism" combines naturally suppressed
Dirac and Majorana masses to achieve light Standard Model neutrinos via a
low-scale seesaw. A key feature of this approach is the presence of multiple
light (order GeV) sterile-neutrinos that mix with the Standard Model. In this
work we study the bounds on these light sterile-neutrinos from processes like
\mu ---> e + \gamma, invisible Z-decays, and neutrinoless double beta-decay. We
show that viable parameter space exists and that, interestingly, key
observables can lie just below current experimental sensitivities. In
particular, a motivated region of parameter space predicts a value of BR(\mu
---> e + \gamma) within the range to be probed by MEG.Comment: 1+26 pages, 7 figures. v2 JHEP version (typo's fixed, minor change to
presentation, results unchanged
Defining the Molecular Basis of Tumor Metabolism: a Continuing Challenge Since Warburg's Discovery
Cancer cells are the product of genetic disorders that alter crucial intracellular signaling pathways associated with the regulation of cell survival, proliferation, differentiation and death mechanisms. the role of oncogene activation and tumor suppressor inhibition in the onset of cancer is well established. Traditional antitumor therapies target specific molecules, the action/expression of which is altered in cancer cells. However, since the physiology of normal cells involves the same signaling pathways that are disturbed in cancer cells, targeted therapies have to deal with side effects and multidrug resistance, the main causes of therapy failure. Since the pioneering work of Otto Warburg, over 80 years ago, the subversion of normal metabolism displayed by cancer cells has been highlighted by many studies. Recently, the study of tumor metabolism has received much attention because metabolic transformation is a crucial cancer hallmark and a direct consequence of disturbances in the activities of oncogenes and tumor suppressors. in this review we discuss tumor metabolism from the molecular perspective of oncogenes, tumor suppressors and protein signaling pathways relevant to metabolic transformation and tumorigenesis. We also identify the principal unanswered questions surrounding this issue and the attempts to relate these to their potential for future cancer treatment. As will be made clear, tumor metabolism is still only partly understood and the metabolic aspects of transformation constitute a major challenge for science. Nevertheless, cancer metabolism can be exploited to devise novel avenues for the rational treatment of this disease. Copyright (C) 2011 S. Karger AG, BaselFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Univ Fed ABC UFABC, CCNH, Santo Andre, BrazilUniversidade Federal de São Paulo UNIFESP, Dept Ciencias Biol, São Paulo, BrazilUniversidade Federal de São Paulo UNIFESP, Dept Bioquim, São Paulo, BrazilUniv Fed Sao Carlos UFSCar, DFQM, Sorocaba, BrazilUniversidade Federal de São Paulo UNIFESP, Dept Ciencias Biol, São Paulo, BrazilUniversidade Federal de São Paulo UNIFESP, Dept Bioquim, São Paulo, BrazilFAPESP: 10/16050-9FAPESP: 10/11475-1FAPESP: 08/51116-0Web of Scienc
